Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Dexmedetomidine (DEX) for Sedation of Subjects ≥1 Month to <17 Years Undergoing MRI Scans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Male or female subject ≥1 month and \<17 years of age.~2. American Society of Anesthesiologists (ASA) Physical Status I, II or III.~3. Requires non-intubated, spontaneous breathing, moderate to deep sedation (NI MDS) for a magnetic resonance imaging (MRI) study with an intensivist, anesthesiologist or other proceduralist in attendance.~4. Duration of the MRI scan is expected to take at least 20 minutes but no more than 3 hours to complete~Key Exclusion Criteria:~1. Pregnant female subjects (including those with an indeterminate or positive pregnancy test); breastfeeding female subjects.~2. Weight on Day 1 before randomization is less than the 10th percentile of weight for age and sex in the US and Japan or is greater than the 95th percentile of weight for age and sex in the US or greater than the 97th percentile of weight for age and sex in Japan based on sponsor-provided growth charts.~3. Planned medical procedure during the MRI scan or post-MRI recovery period.~4. Requires endotracheal intubation or laryngeal mask airway (LMA).~5. Known allergy to eggs, egg products, soybeans or soybean products.~6. SpO2 \<93 % on room air -

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- dexmedetomidine low dose group (Type: EXPERIMENTAL): low dose of dexmedetomidine to be given
- dexmedetomidine middle dose group (Type: EXPERIMENTAL): middle dose of dexmedetomidine to be given
- dexmedetomidine high dose group (Type: EXPERIMENTAL): high dose of dexmedetomidine to be given

Based on this trial design, predict the completion outcome and termination type (if applicable).